Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo Controlled, Double-Blind, Single Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of Oxycyte in Patients With Severe Non-Penetrating Traumatic Brain Injury

X
Trial Profile

A Randomized, Placebo Controlled, Double-Blind, Single Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of Oxycyte in Patients With Severe Non-Penetrating Traumatic Brain Injury

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxycyte (Primary)
  • Indications Traumatic brain injuries
  • Focus Adverse reactions
  • Acronyms STOP-TBI
  • Sponsors Tenax Therapeutics
  • Most Recent Events

    • 11 Sep 2014 Status changed from recruiting to discontinued, as reported in an Oxygen Biotherapeutics media release.
    • 04 Mar 2014 This trial is currently enrolling patients in Israel in the second cohort, according to an Oxygen Biotherapeutics media release.
    • 20 Nov 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top